IBRX: High Short Score, Tight Borrow, and a Founder Holding the Float

ImmunityBio heads into the week with a striking combination: a short score pinned above 83, borrow availability running well below normal, and a founder-CEO who controls nearly two-thirds of the company's shares — leaving a thin tradeable float caught between persistent short sellers and an unusually concentrated ownership structure.

The lending market tells the clearest story about this stock right now. Availability has been chronically tight throughout August and into September, briefly touching near-zero on August 24 before loosening slightly to 18.6% by September 16. That remains well within the "tight" band — fewer than one share is available to borrow for every five already lent out. The 52-week low availability was just 0.015%, showing how compressed this borrow pool can become. Cost to borrow, at 1.19%, is modest in absolute terms, though it edged up 3.9% on the week. The short interest itself — 12.7% of free float, around 125 million shares — has drifted lower for the past month, down roughly 2.8% from mid-August peaks. Short sellers are not piling in; they are slowly trimming. Yet the ORTEX short score, at 83 out of 100, flags that the overall configuration of short positioning, borrow tightness, and days-to-cover (nearly 15, per FINRA) remains under high pressure. The days-to-cover figure is especially notable: a fortnight's worth of average volume would be needed to fully cover the short book.

Options positioning has quietly shifted more defensive over the past two weeks. The put/call ratio moved from around 0.28 in mid-August to 0.376 by September 16 — a 1.35 standard-deviation move above the 20-day average of 0.33. That is not yet an extreme reading (the 52-week high is 0.42), but the direction of travel is consistent with investors hedging more actively into early autumn. The shift coincides with the stock slipping 1.9% on the week and 2.8% on the final session, after a 4.5% gain over the past month. The stock closed at $7.91.

The Street remains constructive on paper, but the analyst data requires context. All three analysts covering IBRX carry Buy ratings, with a mean price target implying roughly 61% upside to current prices. The most recent action — HC Wainwright reiterating a $15 target in early June — is now more than three months old, and the coverage universe is small. D. Boral Capital holds a $23 target that sits well above its peers' range and has not been revisited since May. Factor scores add nuance: the EPS surprise rank in the 95th percentile signals the company has consistently beaten estimates, and the 12-month forward EPS improvement rank of 66 suggests analyst revisions are grinding higher. But the short score rank of 1 and days-to-cover rank of 5 put this name at the extreme cautious end of the universe on positioning metrics.

The ownership picture is the most structurally unusual feature of IBRX. Founder Patrick Soon-Shiong holds a 13D activist stake disclosed at 64.8% of the class as of early August — down slightly from 66.3% previously — with combined vehicles controlling well over 60% of shares outstanding. BlackRock recently added 7.7 million shares through August, and State Street added 3.7 million in the same period, suggesting some passive index flow. Two Sigma built a new position of 6.7 million shares through June. Yet with the founder controlling the vast majority of shares, the true free float is narrow, which mechanically amplifies any short-covering pressure. Recent insider activity — a cluster of pre-arranged 10b5-1 option exercises and sales by two directors in late June and early July — resulted in a 90-day net sale of around $3.9 million worth of stock, though all transactions were under pre-scheduled plans and carry limited signal on conviction.

The next earnings event is scheduled for November 6. IBRX has posted positive one-day moves after three of the past four prints, with gains ranging from 1.4% to 4.5%, and the five-day drift has also been mostly positive. The one exception was a June print that saw the stock fall 2.6% on the day and 6.3% over five sessions. With the ANKTIVA sBLA label-expansion review ongoing and a next quarterly read eight weeks away, the setup to watch is whether the slow unwind in short interest accelerates — or whether the tight borrow pool constrains it — as any catalyst-driven move in either direction will be amplified by the compressed float.